IL-31 Polyclonal Antibody, Biotin, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: SHTLPVRLLR PSDDVQKIVE ELQSLSKMLL KDVEEEKGVL VSQNYTLPCL SPDAQPPNNI HSPAIRAYLK TIRQLDNKSV IDEIIEHLDK LIFQDAPETN ISVPTDTHEC KRFILTISQQ FSECMDLALK SLTSGAQQAT T
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IL-31
• Anti-Human IL-31-specific antibody was purified by affinity chromatography and then biotinylated
• Sandwich ELISA: To detect hIL-31 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.25-1.0 μg/mL of this antibody is required
• This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Human IL-31 (500-P249) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant hIL-31
• Western Blot: To detect hIL-31 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant hIL-31 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• 500-P249BT-1MG will be provided as 2 x 500 μg Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells
• IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor
• In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways
• RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells
• IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.